BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

425 related articles for article (PubMed ID: 10201002)

  • 1. Expression of PRAD1/cyclin D1, retinoblastoma gene products, and Ki67 in parathyroid hyperplasia caused by chronic renal failure versus primary adenoma.
    Tominaga Y; Tsuzuki T; Uchida K; Haba T; Otsuka S; Ichimori T; Yamada K; Numano M; Tanaka Y; Takagi H
    Kidney Int; 1999 Apr; 55(4):1375-83. PubMed ID: 10201002
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cyclin D1/PRAD1 expression in parathyroid adenomas: an immunohistochemical study.
    Hsi ED; Zukerberg LR; Yang WI; Arnold A
    J Clin Endocrinol Metab; 1996 May; 81(5):1736-9. PubMed ID: 8626826
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [A hemodialysis patient with secondary hyperparathyroidism in whom primary parathyroid adenoma was resected 27 years previously].
    Itoh K; Tanaka M; Matsushita K; Tominaga Y
    Nihon Jinzo Gakkai Shi; 2003 Oct; 45(7):706-12. PubMed ID: 14631767
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduced p21, p27 and vitamin D receptor in the nodular hyperplasia in patients with advanced secondary hyperparathyroidism.
    Tokumoto M; Tsuruya K; Fukuda K; Kanai H; Kuroki S; Hirakata H
    Kidney Int; 2002 Oct; 62(4):1196-207. PubMed ID: 12234290
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of cyclin D1 in parathyroid carcinomas, adenomas, and hyperplasias: a paraffin immunohistochemical study.
    Vasef MA; Brynes RK; Sturm M; Bromley C; Robinson RA
    Mod Pathol; 1999 Apr; 12(4):412-6. PubMed ID: 10229506
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Parathyroid hormone immunohistochemistry in dogs with primary and secondary hyperparathyroidism: the question of adenoma and primary hyperplasia.
    van Vonderen IK; Kooistra HS; Peeters ME; Rijnberk A; van den Ingh TS
    J Comp Pathol; 2003 Jul; 129(1):61-9. PubMed ID: 12859909
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Co-expression of parathyroid hormone and chromogranin A in secondary hyperparathyroidism: a functional marker for secretory activity of hyperplastic nodules.
    Tanaka R; Umemura S; Kakuta T; Fujisaki T; Sakai H; Saitoh A; Osamura RY
    Pathol Res Pract; 2003; 199(2):93-9. PubMed ID: 12747471
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Parafibromin, product of the hyperparathyroidism-jaw tumor syndrome gene HRPT2, regulates cyclin D1/PRAD1 expression.
    Woodard GE; Lin L; Zhang JH; Agarwal SK; Marx SJ; Simonds WF
    Oncogene; 2005 Feb; 24(7):1272-6. PubMed ID: 15580289
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular pathogenesis of primary hyperparathyroidism.
    Arnold A; Shattuck TM; Mallya SM; Krebs LJ; Costa J; Gallagher J; Wild Y; Saucier K
    J Bone Miner Res; 2002 Nov; 17 Suppl 2():N30-6. PubMed ID: 12412775
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deletion of 11q23 and cyclin D1 overexpression are frequent aberrations in parathyroid adenomas.
    Hemmer S; Wasenius VM; Haglund C; Zhu Y; Knuutila S; Franssila K; Joensuu H
    Am J Pathol; 2001 Apr; 158(4):1355-62. PubMed ID: 11290553
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of multifunctional cell cycle modulators in advanced secondary hyperparathyroidism.
    Sato T; Kikkawa Y; Hiramitsu T; Yamamoto T; Goto N; Matsuoka S; Nagasaka T; Watarai Y; Uchida K; Tominaga Y
    Ther Apher Dial; 2011 Jun; 15 Suppl 1():26-32. PubMed ID: 21595849
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Parathyroid glands in uraemic patients with refractory hyperparathyroidism: histopathology and p53 protein expression analysis.
    Martin LN; Kayath MJ; Vieira JG; Nosé-Alberti V
    Histopathology; 1998 Jul; 33(1):46-51. PubMed ID: 9726048
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduced immunostaining for the extracellular Ca2+-sensing receptor in primary and uremic secondary hyperparathyroidism.
    Kifor O; Moore FD; Wang P; Goldstein M; Vassilev P; Kifor I; Hebert SC; Brown EM
    J Clin Endocrinol Metab; 1996 Apr; 81(4):1598-606. PubMed ID: 8636374
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of proliferative activity of the parathyroid glands using proliferating cell nuclear antigen in patients with hyperparathyroidism.
    Yamaguchi S; Yachiku S; Morikawa M
    J Clin Endocrinol Metab; 1997 Aug; 82(8):2681-8. PubMed ID: 9253354
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunohistochemical detection of cell cycle regulators, Fhit protein and apoptotic cells in parathyroid lesions.
    Thomopoulou GE; Tseleni-Balafouta S; Lazaris AC; Koutselini H; Kavantzas N; Davaris PS
    Eur J Endocrinol; 2003 Jan; 148(1):81-7. PubMed ID: 12534361
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanism of parathyroid tumourigenesis in uraemia.
    Tominaga Y
    Nephrol Dial Transplant; 1999; 14 Suppl 1():63-5. PubMed ID: 10048455
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Calcium-sensing receptor and apoptosis in parathyroid hyperplasia of patients with secondary hyperparathyroidism.
    Lee HJ; Seo UH; Kim WY; Woo SU; Lee JB
    J Int Med Res; 2013 Feb; 41(1):97-105. PubMed ID: 23569134
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased protein kinase A type Iα regulatory subunit expression in parathyroid gland adenomas of patients with primary hyperparathyroidism.
    Hibi Y; Kambe F; Imai T; Ogawa K; Shimizu Y; Shibata M; Kagawa C; Mizuno Y; Ito A; Iwase K
    Endocr J; 2013; 60(2):215-23. PubMed ID: 23197043
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular pathology of parathyroid tumors.
    Carling T
    Trends Endocrinol Metab; 2001 Mar; 12(2):53-8. PubMed ID: 11167122
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Absence of cyclin D1/PRAD1 point mutations in human breast cancers and parathyroid adenomas and identification of a new cyclin D1 gene polymorphism.
    Hosokawa Y; Tu T; Tahara H; Smith AP; Arnold A
    Cancer Lett; 1995 Jul; 93(2):165-70. PubMed ID: 7621424
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.